

Is serum TWEAK a useful biomarker of neuropsychiatric systemic lupus erythematosus?

Veronika Balajkova¹, Marta Olejarova¹, Radka Moravcova¹, Petr Kozelek², Marie Posmurova², Hana Hulejova¹, Ladislav Senolt¹.

¹Department of Rheumatology, 1st Medical faculty Charles University; ² Psychiatric Clinic of 1st Medical faculty Charles University

Corresponding author:

Veronika Balajkova, MD

Institute of Rheumatology

Na Slupi 4

128 50 Prague 2

Czech Republic

Phone: +420 234 075 336

e-mail: balajkova@revma.cz

Short title: Possible utilisation of TWEAK in NPSLE

Summary

Objective: The aim of this study was to determine the role of the tumor **necrosis** factor like weak inducer of apoptosis (TWEAK) as a serum biomarker of neuropsychiatric involvement in systemic lupus erythematosus (NPSLE).

Methods: Levels of TWEAK levels were measured in sera of 92 patients with systemic lupus erythematosus (SLE), including 28 patients with neuropsychiatric lupus, and in 59 healthy controls using ELISA. All SLE patients underwent rheumatological, neurological and psychiatric assessment.

Results: We found no significant differences in TWEAK levels, between SLE patients and the healthy controls ($p = 0.2411$). Similarly, no difference was observed between subgroup of NPSLE and healthy controls ($p = 0.7658$). The mean SLE disease activity (SLEDAI) was

13.25. No correlations between TWEAK levels with disease activity (SLEDAI; $r = 0.2113$, $p = 0.2805$) or the most common NPSLE manifestations such as headache ($r = 0.2079$), seizures ($r = 0.1101$), cerebrovascular disease ($r = -0.2347$), cognitive dysfunction ($r = 0.1597$) and anxiety ($r = 0.1397$) were observed.

Conclusion: Our data do not support the use of serum TWEAK as a **discriminating** biomarker for NPSLE. The role of the TWEAK in NPSLE remains to be investigated.

Key words: TWEAK, NPSLE, systemic lupus erythematosus, neuropsychiatric **lupus**

Introduction

Systemic lupus erythematosus (SLE) is a chronic multiorgan autoimmune disease with a broad spectrum of clinical manifestations, affecting particularly women of child-bearing age (Frieri, 2013). Neuropsychiatric manifestations include heterogenous variety of neurological and psychiatric syndromes involving central, peripheral and autonomic nervous system (Bortoluzzi et al., 2015; Magro-Checa, Zirkzee, Huizinga, & Steup-Beekman, 2016). The prevalence of neuropsychiatric systemic lupus erythematosus (NPSLE) differs significantly among studies and ranges from 11 % to 95 % of SLE patients (Bortoluzzi et al., 2015; Hanly et al., 2010; Joseph & Scolding, 2010; Kasama, Maeoka, & Oguro, 2016; Sibbitt et al., 2002). This broad span of prevalence of NPSLE depends largely on the use of a different diagnostic and classification criteria, differences in cohort characteristics that may represent important confounders (e.g. age, ethnicity, gender), period of observation, and sometimes, by different clinical focus of clinicians (Perricone et al., 2015; Sarbu et al., 2015). Importantly, NPSLE is associated with increased morbidity and mortality and has tremendously negative impact on health-related quality-of-life of these patients (Hanly et al., 2010; Yazdany, 2011).

In 1999, the American College of Rheumatology (ACR) developed nomenclature and definitions of 19 neuropsychiatric manifestation associated with SLE. ("The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes," 1999). The most common presentations of NPSLE include headache, cognitive dysfunction, cerebrovascular disease, seizures and mood disorders (Bortoluzzi et al., 2015; Hanly, McCurdy, Fougere, Douglas, & Thompson, 2004; Jeong et al., 2015; Pamfil et al., 2015; Popescu & Kao, 2011; Sarbu et al., 2015). Despite the ACR criteria, there is no unified diagnostic test sensitive or specific enough for NPSLE. Therefore, assessment of NPSLE still

remains a clinical challenge and the diagnosis is based on physical examination, neuroimaging methods (MRI), psychiatric and neuropsychological tests and immunological tests.

The pathogenesis of NPSLE is multifactorial and not completely understood. There are two main pathophysiological mechanisms involved in the formation of a neuropsychiatric disability (Hanly, 2014; Zirkzee et al., 2012): Inflammatory mechanisms characterized by the presence of autoantibodies, inflammatory mediators (tumor necrosis factor, cytokines, or immune complex deposits) and non-inflammatory mechanisms including thrombotic or ischemic mechanisms (antiphospholipid antibodies, complement activation) (Belmont, Abramson, & Lie, 1996; Magro-Checa et al., 2016).

A variety of autoantibodies play a significant role in the pathogenesis of NPSLE and their detection may support the diagnosis of NPSLE. Anti-ribosomal P protein antibodies, were significantly associated with psychiatric disorders, especially psychosis and depression (Briani et al., 2009; Isshi & Hirohata, 1998). Some studies described the association between anti-neuronal antibody (anti-NA) and psychosis (Kang et al., 2008; Wilson, Winfield, Lahita, & Koffler, 1979). Anti-phospholipid antibodies, particularly anti-cardiolipin antibodies have been reported in cognitive dysfunction and in reduction of psychomotoric speed in SLE patients (Menon et al., 1999). Anti-NR-2 antibodies directed against NR2a and NR2b subtypes of the N-methyl-D-aspartate (NMDA) receptor are being investigated for cognitive dysfunction. (Kozora, Hanly, Lapteva, & Filley, 2008). Elevated levels of anti-NR-2 antibodies in cerebrospinal fluid in patients with diffuse NPSLE were observed, whereas there were no differences in serum anti-NR2 levels between NPSLE and healthy groups (Arinuma, Yanagida, & Hirohata, 2008). The recent study shows the same association of antibodies to the NR1 subunit of NMDA receptors with NPSLE (Ogawa, Nagai, Sakuma, Arinuma, & Hirohata, 2016). One of the inflammatory mediators that contribute to cognitive dysfunction by disruption of the blood-brain barrier is metalloproteinase 9 (MMP-9) (Kozora et al., 2008).

Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) plays an important role in the pathogenesis of SLE. TWEAK, a member of tumor necrosis factor superfamily, is a multifunctional, pleiotropic and proinflammatory cytokine, which is synthesized as a type II transmembrane protein (Bertin, Stephan, Khrestchatisky, & Desplat-Jego, 2013). Through the activation of its receptor - fibroblast growth factor-inducible molecule 14 (Fn14), TWEAK regulates multiple cellular functions such as cell differentiation, proliferation, migration, angiogenesis, apoptosis or induction of inflammatory cytokines and chemokines (Winkles,

2008; Xu, Zhao, & Liu, 2016). In addition, it has been demonstrated that TWEAK is significantly increased in urine and correlate with renal disease activity of patients with lupus nephritis (Liu et al., 2011; Ruiz-Ortega, Ortiz, & Ramos, 2014; Xuejing et al., 2012).

There are several studies reporting that in animal models TWEAK/Fn14 pathway causes disruption of blood-brain barrier (Wen et al., 2015). In animal models, MRL/lpr Fn14 wild type had impaired cognition increased imobility (depression-like behavior) in comparison to Fn14 knockout mice (Polavarapu, Gongora, Winkles, & Yepes, 2005; Wen et al., 2013; Winkles, 2008).

Based on these data, we aimed to determine the levels of serum TWEAK in patients with SLE, NPSLE and healthy controls to explore the value of serum TWEAK as a biomarker for neuropsychiatric lupus.

Methods

Patients

Patients fulfilling the revised ACR classification criteria for the diagnosis of SLE (Font & Cervera, 1993) were recruited from the outpatient and inpatient clinic at the Institute of Rheumatology, Prague. Age- and sex- matched healthy controls were included. A signed consent form was obtained from each subject prior to initiation of the study. All patients were examined by experienced rheumatologists, neurologists, psychiatrists and clinical psychologist. SLE activity was assessed by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Patients were classified as inactive if the SLEDAI score was < 4. Patients with low active disease had SLEDAI score $\geq 5 < 10$. Active disease was characterized as SLEDAI score ≥ 10 . After exclusion of the other causes (**neuroinfections, tumours etc.**), the diagnosis of NPSLE was based on neuropsychiatric symptoms, serological tests and brain MRI abnormalities according to the ACR nomenclature ("The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes," 1999).

Laboratory analysis

Blood samples were collected from all SLE patients and healthy controls and were immediately centrifuged at 3500 g for 10 minutes and stored at -80°C until analysis. **The**

values of C3, C4 complement components were detected by immunoturbidimetric assays and the anti-dsDNA levels by immunofluorescence technique. The levels of TWEAK were measured by commercially available ELISA (RayBiotech, Inc., Norcross, USA) according to the manufacturers' instructions. Absorbance was detected using the Sunrise ELISA reader (Tecan Group Ltd., Salzburg, Austria) with 450 nm as the primary wavelength. Interassay and intraassay reliability of the Tweak ELISA were CV <10% and <12% respectively. The minimum detectable concentration of TWEAK was 40 pg/ml.

Blood-brain barrier evaluation

The function of the blood-brain barrier was evaluated by magnetic resonance on the T1 weight image after intravenous gadolinium application. If the native and post-contrast image was the same, then we assessed the barrier as unimpaired.

Statistical analysis

TWEAK levels were presented as median (\pm SD). The distribution of data was verified by D'Agostino & Pearson omnibus and Shapiro-Wilk normality test and Mann-Whitney U test was used. A p value < 0.05 was considered statistically significant. The correlation coefficients (r) were calculated using Pearson's correlation. All statistical analyses were performed using GraphPad Prism software.

Results

Ninety-two patients with SLE and 53 age- and sex- adjusted healthy controls were enrolled into this study. Demographics and clinical characteristics of the patients and healthy controls are shown in Table 1.

Neuropsychiatric manifestation occurred in 28 SLE patients (25.76%) meeting the 1999 ACR criteria. SLEDAI score of the NPSLE patients was significantly higher than in remaining SLE patients (13.3 ± 9.16 vs. 5.55 ± 4.74 , $p < 0.001$). The NPSLE group contained 14 patients with high SLEDAI score and 7 patients with low disease activity.

The levels of TWEAK in sera were comparable between patients with SLE and healthy controls (2554 ± 695 vs. 2366 ± 750 pg/ml; $p = 0.241$). In addition, the levels of TWEAK did not differ in patients with NPSLE compared to either SLE patients without neuropsychiatric involvement or healthy controls (2425 vs. 2554 vs. 2366 pg/ml respectively, $p = 0.7658$, $p = 0.5922$) (figure 1).

Additionally, the levels of serum TWEAK in NPSLE patients with and without the most common NPSLE syndromes (headache, seizures, cerebrovascular disease, cognitive dysfunction and anxiety) did not differ (Table 2), either. There was also no correlation between TWEAK serum levels and SLEDAI score in all SLE patients or in NPSLE patients (Table 3). Similarly, no difference of TWEAK level in NPSLE patients with high and low SLEDAI score was observed.

Moreover, no patient had disruption of the blood-brain barrier evaluated by MRI.

Figure 1: Comparison of the serum TWEAK levels between SLE, NPSLE patients and healthy control group (HC)

Discussion

SLE is a chronic autoimmune disease with multiorgan involvement. Although neuropsychiatric impairment is one of the most common manifestations of SLE, the mechanism of pathogenesis remains unclear and a specific biomarker for diagnosis is still missing. Few studies have shown a potential involvement of TWEAK in the pathogenesis of the disease [30,32,40]. It has been shown that urinary TWEAK is a useful biomarker in lupus nephritis and correlates with renal disease activity (El-Shehaby et al., 2011; Gao et al., 2009; Liu et al., 2011; Ruiz-Ortega et al., 2014; Schwartz et al., 2009; Schwartz et al., 2006; Xuejing et al., 2012). More recently TWEAK has become a point of interest in neuropsychiatric involvement.

In our study we examined serum TWEAK levels in patients with SLE including NPSLE and healthy controls. We showed no significant differences in TWEAK levels among these groups. Our data support previous findings of comparable serum TWEAK levels in NPSLE and SLE patients and the non-autoimmune disease group (Fragoso-Loyo, Atisha-Fregoso, Nunez-Alvarez, & Llorente, 2016). However, in this study the authors did not compare the association of TWEAK with specific neuropsychiatric manifestations. Our study analyzed TWEAK levels in patients in the most common NPSLE syndromes but no associations were demonstrated, either.

However, there are few studies demonstrating elevated TWEAK serum levels in SLE patients compared to healthy controls (ElGendi & El-Sherif, 2009; Wang et al., 2012). In addition,

serum TWEAK levels were also higher in SLE patients with vasculitis than those without vasculitis, and so were in comparison between patients with and without headache.

Additionally, Wang et al. examined the expression of TWEAK mRNA in peripheral blood mononuclear cells from patients with SLE and healthy controls, and they found the TWEAK mRNA expression decreased in SLE patients (Wang et al., 2012). In addition, El Gendi et al. described elevated TWEAK levels in SLE patients with lupus nephritis than in patients without renal involvement (ElGendi & El-Sherif, 2009).

Study by Fragoso-Loyo et al. examined the levels of TWEAK in cerebrospinal fluid in NPSLE patients, non-NPSLE patients and controls, where TWEAK levels were only slightly elevated in SLE patients compared with non-autoimmune controls. There was no difference between SLE with and without NPSLE group. Major limitation of their study, despite the large number of patients with NPSLE, was the evaluation of the NPSLE group only as a whole with no regard to the particular clinical NPSLE form.

Another study failed to find any differences in TWEAK levels in the cerebrospinal fluid of multiple sclerosis patients versus patients with non-multiple sclerosis inflammatory diseases. However these data indicated a potential role of TWEAK in inflammatory disorders, including NPSLE (Desplat-Jego et al., 2009).

In our study, we didn't find any correlations between serum TWEAK levels and activity of the disease in the whole group as well as in the NPSLE subgroup. In NPSLE patients this might be due to the fact, that this was the prevalent study, where only a fraction of patients had acute problems. In acute patients the activity of the disease may be certainly high, but in our group there were mostly patients with chronic long-standing problems or neuropsychiatric manifestation in history, so the disease activity was not so high at the NPSLE group generally. Our data are in keeping with lack of differences between active and inactive disease SLE patients demonstrated previously [42]. Similarly, no correlations of serum TWEAK levels and the SLEDAI-2K score at the onset of neuropsychiatric **manifestation** were shown (Fragoso-Loyo et al., 2016).

It was demonstrated, that the major function of TWEAK is modulation of blood-brain barrier permeability (Winkles, 2008). However, none of the NPSLE patients in our study suffered from the blood-brain barrier damage evaluated by MRI. This may also, at least, partially explain the lack of differences and associations demonstrated in our study.

The main limitation of our study is the small group of NPSLE patients and the use of serum samples only with no matching cerebrospinal fluid samples. The cytology analysis of cerebrospinal fluid as a basic neurological examination wasn't available as well.

Despite the fact that our study did not support the hypothesis of that TWEAK is involved in development of NPSLE, there exist data about TWEAK/Fn14 axis (Xu et al., 2016) and other findings (Desplat-Jego et al., 2009; ElGendi & El-Sherif, 2009; Fragoso-Loyo et al., 2016; Wang et al., 2012) indicating its possible role in pathogenesis of the neuropsychiatric lupus. It seems to be ineffective to measure the serum levels of any biomarker of neuropsychiatric lupus as the levels in CSF are often completely different in majority of biomarkers tested in previous studies. As demonstrated for anti-NMDA antibodies, their correlation with NPSLE was observed in CSF only, not in serum (Arinuma et al., 2008). Similarly, levels of certain cytokines were also found to be elevated in NPSLE patients only in the CSF (Yoshio et al., 2016), TWEAK may be the same example. And as mentioned above, the presence of TWEAK in CSF might represent potential discriminating marker for NPSLE but with low specificity. So there is still need for more clinical trials and arguments, including paired (serum and CSF) samples in this issue which may be potential goal of our future studies.

Acknowledgements: The study was supported by the project of the Ministry of Health of Czech Republic for conceptual development of research organization 00023728.

Conflict of Interest: None

References:

- The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. *Arthritis Rheum*, **42**(4), 599-608, 1999.
- ARINUMA Y, YANAGIDA T, HIROHATA S: Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. *Arthritis Rheum*, **58**(4), 1130-1135, 2008.
- BELMONT HM, ABRAMSON SB, LIE JT: Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. *Arthritis Rheum*, **39**(1), 9-22, 1996.
- BERTIN D, STEPHAN D, KHRESTCHATISKY M, DESPLAT-JEGO S: Is TWEAK a Biomarker for Autoimmune/Chronic Inflammatory Diseases? *Front Immunol*, **4**, 489, 2013.
- BORTOLUZZI A, SCIRE CA, BOMBARDIERI S, CANIATTI L, CONTI F, DE VITA S, DORIA A, FERRACCIOLI G, GREMESE E, MANSUTTI E, MATHIEU A, MOSCA M, PADOVAN M, PIGA M, TINCANI A, TOLA MR, TOMIETTO P, VALESINI G, ZEN M,

- GOVONI M: Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. *Rheumatology (Oxford)*, **54(5)**, 891-898, 2015.
- BRIANI C, LUCCHETTA M, GHIRARDELLO A, TOFFANIN E, ZAMPIERI S, RUGGERO S, SCARLATO M, QUATTRINI A, BASSI N, ERMANI N, BATTISTIN L, DORIA A: Neurolupus is associated with anti-ribosomal P protein antibodies: an inception cohort study. *J Autoimmun*, **32(2)**, 79-84, 2009.
- DESDPLAT-JEGO S, FEUILLET L, CREIDY R, MALIKOVA I, RANCE R, KHRESTCHATISKY M, HAHMK, BURKLY LC, PELLETIER J,BOUCRAUT J: TWEAK is expressed at the cell surface of monocytes during multiple sclerosis. *J Leukoc Biol*, **85(1)**, 132-135,2009.
- EL-SHEHABY A, DARWEESH H, EL-KHATIB M, MOMTAZ M, MARZOUK S, EL-SHAARAWY N, EMAD Y: Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. *J Clin Immunol*, **31(5)**, 848-856, 2011.
- EL-GENDI SS, EL-SHERIF WT: Anti-C1q antibodies, sCD40L, TWEAK and CD4/CD8 ratio in systemic lupus erythematosus and their relations to disease activity and renal involvement. *Egypt J Immunol*, **16(1)**, 135-148, 2009.
- Font, J., & Cervera, R. (1993). 1982 revised criteria for classification of systemic lupus erythematosus--ten years later. *Lupus*, **2(5)**, 339-341; discussion 343.
- Fragoso-Loyo, H., Atisha-Fregoso, Y., Nunez-Alvarez, C. A., & Llorente, L. (2016). Utility of TWEAK to assess neuropsychiatric disease activity in systemic lupus erythematosus. *Lupus*, **25(4)**, 364-369.
- FRIERI M: Mechanisms of disease for the clinician: systemic lupus erythematosus. *Ann Allergy Asthma Immunol*, **110(4)**, 228-232, 2013.
- GAO HX, CAMPBELL SR, BURKLY LC, JAKUBOWSKI A, JARCHUM I, BANAS B, SALEEM MA, MATHIESON PW, BERMAN JW, MICHALESON JS, PUTTERMAN C: TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. *Cytokine*, **46(1)**, 24-35, 2009.
- HANLY JG: Diagnosis and management of neuropsychiatric SLE. *Nat Rev Rheumatol*, **10(6)**, 338-347, 2014.
- HANLY JG, MC CURDY G, FOUGERE L, DOUGLASJA, THOMPSON K: Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. *J Rheumatol*, **31(11)**, 2156-2162, 2004.
- HANLY JG, UROWITZ MB, SU L, BAE SC, GORDON C, WALLACE DJ, CLARKE A, BERTNATSKY S, ISENERD D, RAHMAN A, ALACRON GS, GLADMAN DD, FORTIN PR, SANCHZ-GUERRERO J, ROMERO-DIAR J, MERRIL JT, GINZLER E, BRUCE IN, STEINSSON K, KHAMASHTA M, PETRI M, MANZI S, DOOLEY MA, RAMSEY-GOLDMAN R, VAN VOLLENHOVEN R, NIVED O, STURFELT G, ARANOW C, KALUNIAN K, RAMON-CASALS M, ZOMA A, DOUGLAS J, THOMSON K, FAREWELL V: Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. *Ann Rheum Dis*, **69(3)**, 529-535, 2010.
- ISSHI K, HIROHATA S: Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. *Arthritis Rheum*, **41(10)**, 1819-1827, 1998.

- JEONG HW, HER M., BAE JS, KIM SK, LEE SW, KIM HK, KIM D, PARK N, CHUNG WT, LEE SY, CHOE JY, KIM IJ: Brain MRI in neuropsychiatric lupus: associations with the 1999 ACR case definitions. *Rheumatol Int*, **35(5)**, 861-869, 2015.
- JOSEPH FG, SCOLDING NJ: Neurolupus. *Pract Neurol*, **10(1)**, 4-15, 2010.
- KANG EH, SHEN GQ, MORRIS R, METZGER A, LEE EY, LEE YJ, LEE EB, SONG YW: Flow cytometric assessment of anti-neuronal antibodies in central nervous system involvement of systemic lupus erythematosus and other autoimmune diseases. *Lupus*, **17(1)**, 21-25, 2008.
- KASAMA T, MAEOKA A, OGURO N: Clinical Features of Neuropsychiatric Syndromes in Systemic Lupus Erythematosus and Other Connective Tissue Diseases. *Clin Med Insights Arthritis Musculoskelet Disord*, **9**, 1-8, 2016.
- KOZORA E, HANLY JG, LAPTEVA L, FILLEY CM: Cognitive dysfunction in systemic lupus erythematosus: past, present, and future. *Arthritis Rheum*, **58(11)**, 3286-3298, 2008.
- LIU ZC, ZHOU QL, LI XZ, YANG JH, AO X, VEERARAGOO P, ZUO XX: Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus. *Cytokine*, **53(3)**, 295-300, 2011.
- MAGRO-CHECA C, ZIRKZEE EJ, HUIZINGA TW, STEUP-BEEKMAN GM: Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. *Drugs*, **76(4)**, 459-483, 2016.
- MENNON S, JAMESON-SHORTALL E, NEWMAN SP, HALL-CRAGGS MR, CHINN R, ISENBERG DA: A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. *Arthritis Rheum*, **42(4)**, 735-741, 1999.
- OGAWA E, NAGAI T, SAKUMA Y, ARINUMA Y, HIROHATA S: Association of antibodies to the NR1 subunit of N-methyl-D-aspartate receptors with neuropsychiatric systemic lupus erythematosus. *Mod Rheumatol*, **26(3)**, 377-383, 2016.
- PAMFIL C, FANOURLAKIS A, DAMIAN L., RINZIS M, SIDIROPOULOS P, TSIVGOULIS G, REDNIC C, BERTSIAS G, BOUMPAS DT: EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres. *Rheumatology (Oxford)*, **54(7)**, 1270-1278, 2015.
- PERRICONE C, PENDOLINO M, OLIVIERI M, CONTI F, VALESINI G, AALESSANDRI: Neuropsychiatric manifestations associated with anti-endothelial cell antibodies in systemic lupus erythematosus. *Isr Med Assoc J*, **17(3)**, 171-178, 2015.
- POLAVARAPU R, GONGORA MC, WINKLES JA, YEPES M: Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor-kappa B pathway activation. *J Neurosci*, **25(44)**, 10094-10100, 2005.
- POPESCU A, KAO AH: Neuropsychiatric systemic lupus erythematosus. *Curr Neuropharmacol*, **9(3)**, 449-457, 2011.
- RUIZ-ORTEGA M, ORTIZ A, RAMOS AM: Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and kidney disease. *Curr Opin Nephrol Hypertens*, **23(1)**, 93-100, 2014.
- SARBU N, ALOBEIDI F, TOLEDANO P, ESPINOSA G, GILES I, RAHMAN A, YOUSRY T, CAPURRO S, JAGER R, CERVERA R, BARGALLO N: Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. *Autoimmun Rev*, **14(2)**, 153-159, 2015.

- SCHWARTZ N, RUBINSTEIN T, BURKLY LC, COLLINS CE, BLANCO I, SU L, HOJAILI B, MACKAY M, ARANOW C, STOHL W, ROVIN BH, MICHAELSON JS, PUTTERMAN C: Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. *Arthritis Res Ther*, **11(5)**, R143, 2009.
- SCHWARTZ N, SU L, BURKLY LC, MACKAY M, ARANOW C, KOLLAROS M, MICHAELSON JS, ROVIN BH, PUTTERMAN C: Urinary TWEAK and the activity of lupus nephritis. *J Autoimmun*, **27(4)**, 242-250, 2006.
- SIBBIT WL JR, BRANDT JR, JOHNSON CR, MALDONADO ME, PATEL SR, FORD CC, BANKHURST AD, BROOKS WM: The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. *J Rheumatol*, **29(7)**, 1536-1542, 2002.
- WANG C, CHEN LL, PAN HF, LENG RX, QIN WT, YE DQ: Expression of human tumor necrosis factor-like weak inducer of apoptosis in patients with systemic lupus erythematosus. *Clin Rheumatol*, **31(2)**, 335-339, 2012.
- WEN J, DOERNER J, WEIDENHEIM K., XIA Y, STOCK A, MICHAELSON JS, BURKLY LC, GULINELLO M, PUTTERMAN C: TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice. *J Autoimmun*, **60**, 40-50, 2015.
- WEN J, XIA Y, STOCK A, MICHAELSON JS, BURKLY LC, GULINELLO M, PUTTERMAN C: Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway. *J Autoimmun*, **43**, 44-54, 2013.
- WILSON HA, WINFIELD JB, LAHITA RG, KOFFLER D: Association of IgG anti-brain antibodies with central nervous system dysfunction in systemic lupus erythematosus. *Arthritis Rheum*, **22(5)**, 458-462, 1979.
- WINKLES JA: The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. *Nat Rev Drug Discov*, **7(5)**, 411-425, 2008.
- XU WD, ZHAO Y, LIU Y: Role of the TWEAK/Fn14 pathway in autoimmune diseases. *Immunol Res*, **64(1)**, 44-50, 2016.
- XUEJING Z, JIAZHEN T, JUN L, XIANGQING X, SHUGUANG Y, FUYOU L: Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. *J Biomed Biotechnol*, 359647, 2012.
- YAZDANY J: Health-related quality of life measurement in adult systemic lupus erythematosus: Lupus Quality of Life (LupusQoL), Systemic Lupus Erythematosus-Specific Quality of Life Questionnaire (SLEQOL), and Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL). *Arthritis Care Res (Hoboken)*, **63 Suppl 11**, S413-419, 2011.
- YOSHIO T, OKAMOTO H, KURASAWA K, DEI Y, HIROHATA S, MINOTA S: IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus. *Lupus*, **25(9)**, 997-1003, 2016.
- ZIRKZEE EJ, STEUP-BEEKMAN GM, VAN DER MAST RC, BOLLEM EL, VAN DER WEE NL, BAPTIST E, SLEE TM, HUISMAN MV, MIDDELKOOP HA, LUYENDIJK J, VAN BUCHEM MA, HUIZINGA TW: Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. *J Rheumatol*, **39(11)**, 2118-2126, 2012.

Figure 1: Comparison of the serum TWEAK levels between SLE, NPSLE patients and healthy control group (HC)




Table 1. Demographics and clinical characteristics and Characteristics of SLE patients,

NPSLE subgroup and healthy controls.

	SLE n = 64	NPSLE n = 28	Healthy controls n = 53
Age ^a	41.62 ± 13.25	44.92 ± 13.80	45 ± 14.17
Female/male	58/6	26/2	44/9
SLE disease duration (years) ^a	3.93 ± 10.03	1.92 ± 2.96	
Cumulative disease involvement			
Neuropsychiatric	0	28	
Cutaneous	41 (64.06%)	19 (67.85%)	
Renal	34 (53.12%)	10 (35.71%)	
Articular	56 (87.5%)	25 (89.28%)	
Hematologic	52(81.25%)	22(78.57%)	
Serositis	24 (37.5%)	13 (46.42%)	
Disease parameters at the time of study			
anti ds-DNA positivity	38 (59.37%)	10 (35.71%)	
C3 ^{a,b}	0.90±0.26	0.95±0.29	
C4 ^{a,c}	0.17±0.09	0.19±0.10	
SLEDAI index ^a	5.55 ± 4.74	13.3 ± 9.16	
High >14	8 (12.5%)	14 (50.0%)	
Low <7	41 (64.06%)	7 (25.0%)	

^a mean ± standard deviation
^b normal value 0,90-1,80 g/l
^c normal value 0,10-0,40 g/l

Table 2. Comparison of the serum TWEAK levels of the most common NPSLE.

NPSLE syndrome	Headache	CVD ^b	Seizures	CD ^c	Anxiety
positive	18 (64.28%)	6 (21.42%)	12 (42.85%)	15 (53.57%)	14 (50%)
TWEAK ^a	2711 (±956.4)	2253 (±338.9)	2695 (±1027)	2755 (±1025)	2625 (±859.2)
p value (two-tailed)	0.3081	0.2484	0.5922	0.5012	0.4871

^a TWEAK serum level is reported as mean± standard deviation in pg/ml, ^b Cerebrovascular disease ^c Cognitive dysfunction

The patients might have had > 1 manifestation

Table 3. Correlation NPSLE TWEAK level with disease activity (SLEDAI index).

	TWEAK ^a 2425 (±810)	
SLEDAI index ^b 13.3 (± 9.16)	r	P
	0.2113	0.2805

r = correlation coefficient p = p value (two tailed) ^a TWEAK serum level is reported as mean± standard deviation in pg/ml,
^b mean ± standard deviation